



United States of America
976 7F O @ U G 2 6 7 U B E C H R E D U
WASHINGTON, D.C. 20580

Office of the Secretary

Q1Y™ eCxe: UDS eOJ
P3Y\$™ eCxe: U4JDUHSePU

F e U A b b v e , I n c . a n d A l l e r g a n , p l c , 8 J 3 U B y e U D Y U . # U # * . U B E , ' (U

6 e S U B Y™ eCxe-U

KzTCCBYAU© UzeUy ~ ecUzTUDYAUAY™ }»eald e 1/4 c)S "DUUyccel»YCU }zUfU
3Yc eOJF -ae-ll. AeaYDUzeU4Y™ : YfUWle»e(SCT» : »Uyc]e] . [S-] }Owt Y- (OYZMe]c]H]U
a -Y Y ealS-af }YcUj O''e-vscU \IU zelB Y™ , : YcUe]el ebUzelU -Y faUj -af }YcUyU
H e f f y } - c e U U Y W e g y a 4 Y U e h i e a t e / 3/4 E J 1/4 U 1/2 fi Y

The Commission is satisfied that the Order in this matter protects against the potential for anticompetitive harm as a result of AbbVie's acquisition of Allergan. In our view, based on a thorough and extensive investigation that considered all of the theories raised in comments submitted by the public, the relief contained in the Order appropriately addresses the competition concerns arising from the acquisition.

In its work on antitrust and consumer protection issues, the Commission finds it helpful to hear from a variety of sources, and we appreciate your interest in this matter.

By direction of the Commission, Commissioner Chopra dissenting and Commissioner Slaughter not participating.

April Tabor
Acting Secretary